Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia

Over 26,000 people will face a new diagnosis of acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) in 2020 in the U.S. alone, and only a minority will be long-term survivors [1]. Am...

• Publication year

  2020

• Venue

  Leukemia and Lymphoma

• Publication date

  2020-07-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/10428194.2020.1786553PMID 32627634PMCID PMC7686042
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer statistics, 2020

  2020cited by this paper
• Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.

  2019cited by this paper
• Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330

  2018cited by this paper
• Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use

  2018cited by this paper
• Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

  2018cited by this paper
• Gemtuzumab ozogamicin in acute myeloid leukemia

  2017cited by this paper
• Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances.

  2017cited by this paper
• Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia

  2016cited by this paper
• Designed BH3 Peptides with High Affinity and Specificity for Targeting Mcl-1 in Cells

  2014cited by this paper
• BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia

  2013cited by this paper
• Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-gamma1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line.

  2010cited by this paper
• Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

  2010cited by this paper
• Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.

  2006cited by this paper
• The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin.

  2004cited by this paper

• Navigating the Landscape of Resistance Mechanisms in Antibody–Drug Conjugates for Cancer Treatment

  2025influential citation
• Development of a Novel Biomarker Platform for Profiling Key Protein–Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs

  2025cites this paper
• Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059

  2024cites this paper
• Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET® CC-96191

  2024cites this paper
• DNTT-mediated DNA Damage Response Drives Inotuzumab Ozogamicin Resistance in B-cell Acute Lymphoblastic Leukemia.

  2024cites this paper
• Effects of some flavor enhancer food additives on expression of cancer-related genes in MCF-7 and MCF-12A cells

  2023cites this paper
• Antibody–drug conjugates come of age in oncology

  2023cites this paper
• A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy

  2023cites this paper
• A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials

  2022cites this paper
• Ganoderma lucidum Spore Polysaccharide Inhibits the Growth of Hepatocellular Carcinoma Cells by Altering Macrophage Polarity and Induction of Apoptosis

  2021cites this paper
• Multiplex Single‐Cell Analysis of Cancer Cells Enables Unbiased Uncovering Subsets Associated with Cancer Relapse: Heterogeneity of Multidrug Resistance in Precursor B‐ALL

  2021cites this paper
• CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin

  2021cites this paper